Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESTID vs CHOLESTYRAMINE LIGHT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
FDA: Primary hyperlipidemia (Fredrickson Type IIa) as adjunctive therapy to diet to reduce elevated serum LDL cholesterol,FDA: Relief of pruritus associated with partial biliary obstruction or primary biliary cirrhosis,Off-label: Diarrhea associated with bile acid malabsorption (e.g., post-cholecystectomy diarrhea, Crohn's disease),Off-label: Digoxin toxicity (to interrupt enterohepatic circulation, though rarely used today)
5-10 g orally once or twice daily, maximum 30 g/day.
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Not metabolized; acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Not significantly absorbed; binding not applicable
Not applicable (non-absorbed); no plasma protein binding.
Not applicable (non-absorbed; confined to gastrointestinal lumen)
Not applicable (non-absorbed); confined to gastrointestinal lumen.
Oral: <0.05% (negligible systemic absorption)
Oral: <0.04% (minimal systemic absorption due to large molecular weight and quaternary ammonium structure).
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
No dosage adjustment required for renal impairment.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
No specific dosage adjustment recommended; caution in patients with severe hepatic impairment.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
240 mg/kg/day orally in 2-3 divided doses, not to exceed 8 g/day; adjust based on clinical response.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
Start at low end of dosing range (4 g/day) and titrate slowly; monitor for constipation and drug interactions.
No FDA black box warning.
No FDA boxed warning.
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
May reduce absorption of fat-soluble vitamins (A, D, E, K), requiring supplementation,May cause hyperchloremic metabolic acidosis, especially in children with large doses,May cause constipation, which can aggravate hemorrhoids; discontinue if impaction occurs,May interfere with absorption of other drugs; administer other medications at least 1 hour before or 4-6 hours after cholestyramine,Use with caution in patients with phenylketonuria (products may contain aspartame)
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
Complete biliary obstruction (ineffective and may cause harm),Hypersensitivity to cholestyramine or any component of the formulation
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
Cholestyramine binds to bile acids in the gut and can also bind to dietary fats and fat-soluble vitamins. Administer with food to reduce GI side effects. High-fat meals may reduce efficacy by competing for binding. Avoid concurrent intake with grapefruit juice (may alter binding). Separate ingestion from high-fat, large meals by at least 1 hour.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across all trimesters.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
Breastfeeding safety: Compatible due to negligible systemic absorption. M/P ratio: Not applicable (not absorbed). No adverse effects reported in breastfed infants.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
No dose adjustment required in pregnancy due to lack of systemic absorption. Ensure adequate intake of fat-soluble vitamins and consider folic acid supplementation due to potential binding.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
Cholestyramine Light contains aspartame; contraindicated in phenylketonuria. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. Monitor for hyperchloremic metabolic acidosis, especially in renal impairment. Constipation is common; encourage fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
Take exactly as prescribed, usually mixed with water or non-carbonated liquid; do not swallow dry powder.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine to ensure proper absorption.,Drink plenty of fluids and eat fiber-rich foods to prevent constipation.,Report unusual bleeding, bruising, or dark urine (signs of vitamin K deficiency).,This product contains aspartame; avoid if you have phenylketonuria.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESTID vs CHOLESTYRAMINE LIGHT, answered by our medical review team.
COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. CHOLESTYRAMINE LIGHT is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESTID and CHOLESTYRAMINE LIGHT depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. The standard adult dose of CHOLESTYRAMINE LIGHT is: 4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESTID and CHOLESTYRAMINE LIGHT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. CHOLESTYRAMINE LIGHT is classified as Category C. Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.